NVO Stock Recent News

Over the weekend, President Trump offered to delay implementation of a new 50% tariff on imports from the European Union. The tariff, which was supposed to begin on June 1, now won't take effect until July 9.

Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.

Despite Lars Fruergaard Jørgensen's resignation as Novo Nordisk's CEO, its stock price has risen 10% over the past two weeks. I believe this is due to the strong performance of its GLP-1 products and the successes achieved in developing its clinical-stage projects. So, the semaglutide franchise's total sales reached DKK 50 billion in the first quarter of 2025, an increase of 18.7% year-on-year.

GLP-1 drugs for weight loss and treating diabetes show promise for an ever-expanding list of diseases.

The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.

Mizuho's Jared Holz joins 'Fast Money' to talk what is next for Novo Nordisk as the stock struggles.

NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid intensifying GLP-1 competition.

Novo Nordisk A/S (NOVO-B) has entered the 18th and final phase of its long-term Weekly Adhishthana Cycle, marking a potentially transformative period. While the weekly charts point to a possible Nirvana, which represents the highest price of the stock throughout its 18 phases, there are conflicting signals coming from the monthly charts as well as the company's NYSE ADR (NVO).

These dividend stocks can significantly amplify the compounding of your portfolio.

Novo Nordisk said on Thursday it is offering self-paying patients who are new to its weight loss drug Wegovy their first month of medicine for $199 through June 30.